Table 3.
Detailed data on anticoagulant therapy in the study group. Abbreviations: NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist.
| All n = 2971 |
Apixaban n = 953 |
Dabigatran n = 819 |
Rivaroxaban n = 1199 |
p | |
|---|---|---|---|---|---|
| Reduced dose | 1071 (36.0) | 334 (35) | 325 (39.7) | 412 (34.4) | 0.0372 |
| Antiplatelets with NOAC | 399 (13.4) | 141 (14.8) | 96 (11.7) | 162 (13.5) | 0.1661 |
| Treatment before hospitalization | |||||
| The same NOAC | 2429 (81.8) | 649 (68.1) | 724 (88.4) | 1056 (88.1) | < 0.0001 |
| Another NOAC | 82 (2.8) | 62 (6.5) | 13 (1.6) | 7 (0.6) | < 0.0001 |
| VKA | 81 (2.7) | 48 (5.0) | 14 (1.7) | 19 (1.6) | < 0.0001 |
| Antiplatelets only | 98 (3.3) | 51 (5.4) | 19 (2.3) | 28 (2.3) | < 0.0001 |
| None | 281 (9.5) | 143 (15.0) | 49 (6.0) | 89 (7.4) | < 0.0001 |